ABL1 and acute lymphoblastic leukemia: Retrospective analysis of a phase I/II clinical trial of nilotinib in patients with BCR-ABL positive CML or acute lymphoblastic leukemia (ALL) found that UGT1A1*28 homozygotes had a significant risk of grade 3/4 hyperbilirubinemia [28].